- Home
- BQ vs TIVC Comparison
BQ vs TIVC Comparison
Compare BQ & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BQ | TIVC |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BQ | TIVC |
|---|---|---|
| Price | $0.79 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 169.7K | ★ 222.5K |
| Earning Date | 01-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.65 | $0.75 |
| 52 Week High | $72.74 | $5.60 |
Technical Indicators
Market Signals| Indicator | BQ | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 69.31 |
| Support Level | $0.68 | $0.79 |
| Resistance Level | $0.88 | $2.70 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 57.19 | 100.00 |
Price Performance
Historical ComparisonAbout BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.